Communiqués Candel Therapeutics, Inc.

Actions

CADL

US1374041093

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/08/2026			Varia. 5j.	Varia. 1 janv.
13,13 ^USD	+6,32%		+12,03%	+132,39%

14/08	Candel Therapeutics, Inc. : BofA Securities maintient sa recommandation à l'achat	ZM
13/08	Candel Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

13/08	Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	GL
03/08	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
03/08	Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026	GL
30/07	Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston	AQ
29/07	Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston	GL
09/07	Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 8, 2026	AQ
08/07	Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
01/07	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
01/07	Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec in Advanced Non-Small Cell Lung Cancer	AQ
30/06	Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors	GL
25/06	Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer	GL
02/06	Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer	GL
01/06	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
15/05	Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting	GL
15/05	Candel Therapeutics : CADL AUA Investor Call final deck 3PM 5.14.26 IR	PU
14/05	Candel Therapeutics : Website Candel May 2026 Corporate Presentation 230AM 05.14.26 IR	PU
14/05	Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights	GL
13/05	Candel Therapeutics to Present at Upcoming Investor Conferences	GL
04/05	Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting	GL
01/05	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
29/04	Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer	GL
14/04	Candel Therapeutics : Website Candel April 2026 Corporate Presentation 230PM 041426 IR	PU
02/04	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
17/03	Candel Therapeutics : Website Candel March 2026 Corporate Presentation 031626 IR	PU
17/03	Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors	GL